EUCTR2017-005053-37-ES进行中（未招募）1 期
Effect on the functional capacity of treatment with intravenous iron carboxymaltose or oral iron sucrosomial in patients with heart failure with depressed left ventricular ejection fraction and iron deficiency anemia. - IVOFER
José Luis Morales Rull. Institut de Recerca Biomèdica de Lleida (IRBLleida)0 个研究点目标入组 572 人开始时间: 2018年8月10日最近更新:
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 572
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •1. Subjects with stable chronic HF (NYHA II/IV functional class) on optimal background therapy (as determined by the investigator) for at least 4 weeks with no dose changes of heart failure drugs during the last 2 weeks (with the exception of diuretics). In general, optimal
- •pharmacological treatment should include an angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker and a beta blocker unless contraindicated or not tolerated and diuretic if indicated.
- •2. Left ventricular ejection fraction >45% (value within 3 months of planned date of randomization).
- •3. BNP >100 pg/mL and/or N-terminal-pro-BNP >400 pg/mL at the screening visit.
- •4. Subject must be capable of completing the 6MWT.
- •5. Screening serum ferritin <100 ng/mL or 100–300 ng/mL with transferrin saturation <20%.
- •6. At least 18 years of age.
- •7. Before any study-specific procedure, the appropriate written informed consent must be obtained.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 572
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Subject has known sensitivity to any of the products to be administered during dosing.
- •2. History of acquired iron overload.
- •3. History of erythropoietin-stimulating agent, i.v. iron therapy, and/or blood transfusion in previous 6 weeks prior to randomization.
- •4. Oral iron therapy at doses >100 mg/day in previous 1 week prior to randomization. Note: ongoing use of multivitamins containing
- •iron <75 mg/day is permitted.
- •5. Body weight =/<35 kg.
- •6. Exercise training programme(s) in the 3 months prior to screening or planned in the next 6 months.
- •7. Subject at an immediate need of transfusion or haemoglobin >/= 15 g/dL.
- •8. Known active bacterial infection.
- •9. Chronic liver disease (including active hepatitis) and/or screening alanine transaminase or aspartate transaminase above three times the upper limit of the normal range.
- •10. Subjects with known hepatitis B surface antigen positivity and/or hepatitis C virus ribonucleic acid positivity.
- •11. Vitamin B12 and/or serum folate deficiency. If deficiency-corrected subject may be rescreened for inclusion.
- •12. Subjects with known seropositivity to human immunodeficiency virus.
- •13. Clinical evidence of current malignancy with exception of basal cell or squamous cell carcinoma of the skin, and cervical intraepithelial neoplasia.
- •14. Currently receiving systemic chemotherapy and/or radiotherapy.
- •15. Renal dialysis (previous, current, or planned within the next 6 months).
- •16. Unstable angina pectoris as judged by the investigator; severe valvular or left ventricular outflow obstruction disease needing intervention; atrial fibrillation/flutter with a mean ventricular response rate at rest >100 beats per minute.
- •17. Acute myocardial infarction or acute coronary syndrome, transient ischaemic attack, or stroke within the last 3 months prior to randomization.
- •18. Coronary artery bypass graft, percutaneous intervention (e.g. cardiac, cerebrovascular, and aortic; diagnostic catheters are allowed), or major surgery, including thoracic and cardiac surgery, within the last 3 months prior to randomization.
- •19. Subject currently is enrolled in or has not yet completed at least 30 days since ending other investigational device or drug study(ies), or subject is receiving other investigational agent(s).
- •20. Subject of childbearing potential who is pregnant (e.g. positive human chorionic gonadotropin test) or is breastfeeding.
- •21. Subject is not willing to use adequate contraceptive precautions during the study and for up to 5 days after the last scheduled dose of study medication.
- •22. Subject previously randomized to this study. Note: subjects may be rescreened if they fail any of the screening procedures. If rescreened, all tests must fall inside the maximum specified screening windows for each criterion.
- •23. Subject will not be available for all protocol-specified assessments.
- •24. Subject has any kind of disorder that compromises the ability of the subject to give written informed consent and/or to comply with study procedures.
- •25. Lactose intolerance.
- •26. Pregnant woman.
研究者
相似试验
已完成
不适用
Effects of stretching exercises in patients with Multiple SclerosisMultiple sclerosisIRCT20190702044079N1niversity of social welfare and rehabilitation sciences22
已完成
不适用
A comparative study of the therapeutic effects of continuous and pulsed laser light on wound healing rates.Injury, Occupational Diseases, Poisoning: Wound healingInjury, Occupational Diseases, PoisoningWound healingISRCTN80835416Record Provided by the NHSTCT Register - 2005 Update - Department of Health (UK)80
已完成
2 期
?A comparative study of the therapeutic effect of the propolis vaginal cream and metronidazol vaginal gel on bacterial vaginosis in reproductive aged women referring to gynecology clinicsAcute vaginitisBacterial Vaginosis.IRCT201408202325N2Islamic Azad University of Isfahan(Khorasgan Branch)100
已完成
3 期
A comparison study of the therapeutic effect of topical steroid and honey plus coffee on Oral Mucositis after chemotherapy and/or radiotherapy.K13.7 Other and unspecified lesions of oral mucosa.K13.7IRCT201104074737N3Dr. Mohammad Ali Raeessi + Baqiyatallah University of Medical Sciences75
已完成
不适用
A novel weight-bearing resistance training program for inpatient aged care rehabilitation: comparison with a non-weight-bearing program in a randomised controlled trial.Frailty in older peoplePhysical Medicine / Rehabilitation - Other physical medicine / rehabilitationACTRN12605000414617Bankstown-Lidcombe Hospital90